ABIVAX's Obefazimod Hits Phase 3 Milestone in Ulcerative Colitis, Extending Financial Runway to 2027
French biotech ABIVAX reports positive Phase 3 results for its lead drug obefazimod in ulcerative colitis, meeting key secondary endpoints with a clean safety profile. With funding secured through late 2027, the company plans to advance pivotal maintenance and Crohn's disease trials, reshaping its investment narrative.